image narrates my story

Bharat Biotech to conduct clinical trial of Covaxin on children above 12 years

Share this post on:

New Delhi, 04 January: Bharat Biotech Company will soon start a clinical trial of Covaxin for Covid-19 on children above 12 years of age.

The Drugs Controller General of India (DCGI) has allowed Covaxin, an indigenously developed coronovirus vaccine from Hyderabad-based Bharat Biotech, to conduct clinical trials on children over 12 years of age. Bharat Biotech vaccine can be given to the age group of 12 years or above.

In a press conference on Monday, Bharat Biotech Managing Director Krishna Ella said that Covaxine has to be given in two doses. Covaxin is the first vaccine in the world that can also be given to children. Bharat Biotech will soon test Covaxin on children above 12 years.

On the question of side effects of Covaxin, Krishna Ella said that only 10 per cent of the people in the trial of Covaxin had an allergic reaction while the rest of the vaccine had adverse effects in 60-70 per cent. AstraZeneca is also giving fever medicines to all volunteers to suppress allergic reactions whereas Covaxin did nothing of the sort. Covaxin is 200 percent safe.